Table 2: Adverse effects associated with gefitinib.

Adverse effectNo. of studiesModelRR (95%CI)P valueHeterogeneity (p,I2)Conclusion

Diarrhea6Fixed4.29(1.96, 9.41)0.0003P=0.62; I2=0%Positive
Mucositis6Fixed1.20 (0.96, 1.50)0.10P=0.86, I2=0%Negative
Skin toxicity6Fixed1.71 (1.06, 2.74)0.03P=0.24; I2=26%Positive
Dysphagia4Fixed0.90 (0.57, 1.42)0.65P=0.17; I2=40%Negative
Nausea4Fixed0.98 (0.47, 2.02)0.95P=0.55; I2=0%Negative
Vomiting4Fixed1.01 (0.49, 2.10)0.97P=0.60; I2=0%Negative
Weight loss3Fixed0.48 (0.12, 1.92)0.30P=0.73; I2=0%Negative
Fibrosis2Fixed0.77 (0.43, 1.40)0.40P=1.00; I2=0%Negative
Neutropenia2Fixed0.97 (0.46, 2.07)0.94P=0.92; I2=0%Negative
Leukopenia2Fixed1.20 (0.60, 2.39)0.60P=0.88; I2=0%Negative
Oedema2Fixed1.00 (0.55, 1.82)0.99P=0.96; I2=0%Negative
Xerostomia2Fixed0.94 (0.41, 2.16)0.88P=0.60; I2=0%Negative
Fatigue3Fixed0.97 (0.54, 1.72)0.91P=0.27; I2=24%Negative
Anemic2Random1.00 (0.04, 22.86)1.00P=0.08; I2=67%Negative
Hemorrhage2Random1.30 (0.07, 24.23)0.86P=0.11; I2=61%Negative